Vaxcyte Inc (PCVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Vaxcyte Inc (PCVX) Earnings: Report Dates and Results
Vaxcyte (PCVX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Vaxcyte reported EPS of -$1.99, below the -$1.84 estimate. It beat the EPS estimate in 0 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PCVX has an expected report date of Feb 22, 2027.
PCVX Earnings Call
The latest PCVX earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 27 quarters below that had an estimate, PCVX beat 11 and missed 16. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 94.06% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.99 | -$1.84 | -$2.68 - -$1.67 | -8.15% | Miss | N/A | 7 | 2 up, 0 down | Nov 4, 2026 |
| Jun 30, 2026 | -$1.97 | -$1.47 | -$2.55 - -$1.47 | -34.01% | Miss | N/A | 7 | 0 up, 0 down | Aug 5, 2026 |
| Mar 31, 2026 | -$2.30 | -$1.77 | -$1.96 - -$1.58 | -29.94% | Miss | N/A | 5 | 1 up, 1 down | May 6, 2026 |
| Dec 31, 2025 | -$1.80 | -$1.47 | -$1.90 - -$1.12 | -22.45% | Miss | N/A | 6 | 0 up, 3 down | Feb 24, 2026 |
| Sep 30, 2025 | -$1.56 | -$1.24 | -$1.52 - -$1.00 | -25.81% | Miss | N/A | 6 | 1 up, 1 down | Nov 4, 2025 |
| Jun 30, 2025 | -$1.22 | -$1.16 | -$1.29 - -$1.01 | -5.17% | Miss | N/A | 5 | 0 up, 0 down | Aug 6, 2025 |
| Mar 31, 2025 | -$1.04 | -$0.97 | -$1.14 - -$0.81 | -7.22% | Miss | N/A | 2 | 0 up, 0 down | May 7, 2025 |
| Dec 31, 2024 | -$1.02 | -$0.99 | -$1.15 - -$0.91 | -2.58% | Miss | N/A | 5 | N/A | Feb 25, 2025 |
| Sep 30, 2024 | -$0.83 | -$0.99 | -$1.35 - -$0.88 | +16.16% | Beat | N/A | 8 | 1 up, 0 down | Nov 5, 2024 |
| Jun 30, 2024 | -$1.10 | -$1.00 | -$1.10 - -$0.86 | -10.00% | Miss | N/A | 8 | 0 up, 0 down | Aug 6, 2024 |
| Mar 31, 2024 | -$0.85 | -$1.06 | -$1.72 - -$0.84 | +19.81% | Beat | N/A | 8 | 0 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$1.82 | -$1.07 | -$1.61 - -$0.54 | -70.09% | Miss | N/A | 8 | 0 up, 0 down | Feb 27, 2024 |
| Sep 30, 2023 | -$0.91 | -$0.84 | -$0.96 - -$0.73 | -8.33% | Miss | N/A | 8 | 0 up, 0 down | Nov 6, 2023 |
| Jun 30, 2023 | -$0.70 | -$0.77 | -$0.86 - -$0.61 | +9.09% | Beat | N/A | 8 | 0 up, 0 down | Aug 8, 2023 |
| Mar 31, 2023 | -$0.70 | -$0.88 | -$0.97 - -$0.76 | +20.45% | Beat | N/A | 7 | 0 up, 0 down | May 8, 2023 |
| Dec 31, 2022 | -$1.02 | -$0.93 | -$1.20 - -$0.78 | -9.68% | Miss | N/A | 7 | 0 up, 2 down | Feb 27, 2023 |
| Sep 30, 2022 | -$0.93 | -$0.85 | -$0.86 - -$0.80 | -9.41% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2022 |
| Jun 30, 2022 | -$0.80 | -$0.66 | N/A | -21.21% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2022 |
| Mar 31, 2022 | -$0.68 | -$0.66 | -$0.75 - -$0.56 | -3.03% | Miss | N/A | 3 | 0 up, 0 down | May 9, 2022 |
| Dec 31, 2021 | -$0.55 | -$0.56 | -$0.62 - -$0.50 | +1.79% | Beat | N/A | 3 | 0 up, 0 down | Feb 28, 2022 |
| Sep 30, 2021 | -$0.51 | -$0.58 | -$0.59 - -$0.47 | +12.07% | Beat | N/A | 3 | 3 up, 0 down | Nov 10, 2021 |
| Jun 30, 2021 | -$0.46 | -$0.53 | -$0.58 - -$0.46 | +13.21% | Beat | N/A | 3 | N/A | Aug 11, 2021 |
| Mar 31, 2021 | -$0.41 | -$0.56 | -$0.56 - -$0.41 | +26.79% | Beat | N/A | 2 | N/A | May 11, 2021 |
| Dec 31, 2020 | -$0.41 | -$0.54 | -$0.60 - -$0.46 | +24.07% | Beat | N/A | 3 | N/A | Mar 29, 2021 |
| Sep 30, 2020 | -$0.41 | -$0.44 | -$0.48 - -$0.42 | +6.82% | Beat | N/A | 3 | N/A | Nov 12, 2020 |
| Jun 30, 2020 | -$1.72 | -$1.27 | -$2.05 - -$0.66 | -35.43% | Miss | N/A | 3 | N/A | Aug 12, 2020 |
| Mar 31, 2020 | -$0.29 | -$4.88 | N/A | +94.06% | Beat | N/A | N/A | N/A | Jun 15, 2020 |
| Dec 31, 2019 | -$1.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.62, after -$3.80 the year before. It was -$1.08 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.62 | N/A |
| Dec 31, 2024 | -$3.80 | N/A |
| Dec 31, 2023 | -$4.13 | N/A |
| Dec 31, 2022 | -$3.43 | N/A |
| Dec 31, 2021 | -$1.93 | N/A |
| Dec 31, 2020 | -$2.83 | N/A |
| Dec 31, 2019 | -$1.08 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 7,900 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 7,911 | 15 | |
| 2024Q4 | Dec 31, 2024 | 8,681 | 11 |
2025Q4 Earnings Call
Opening remarks
Andrew Guggenhime President and CFO Thank you, operator. Good afternoon, everyone, and thanks for joining us today as we review our 2025 results and provide a business update. I am joined by our Chief Executive Officer, Grant Pickering; and our Executive Vice President and Chief Operating Officer, Jim Wassil. Earlier today, we issued a news release announcing our results. Copies of this and our other news releases, latest corporate presentation and SEC filings can be found in the Investors and Media section of our website. Before we begin, I'd like to remind you that during this call, we'll be making certain forward-looking statements about Vaxcyte, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with these statements, please see our press release issued today as well as our most recent filings with the SEC, including the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and any subsequent reports filed with the SEC. With that, I'll turn the call over to Grant Pickering. Grant?
Grant Pickering CEO Thanks, Andrew. As we close out 2025 and look forward to multiple clinical readouts beginning later this year, I'm proud of the progress we made across the company, particularly within our pneumococcal conjugate vaccine or PCV franchise. Despite decades of vaccination efforts, pneumococcal disease continues to drive substantial morbidity and mortality worldwide, particularly among young children and older adults. While current vaccines have made a meaningful impact, gaps in serotype coverage persist and the public health need for broader spectrum protection remains clear. Consistent with that need, we are seeing accelerating growth in the adult PCV market, driven by expanded age group recommendations in the United States and increasing international adoption of adult PCV vaccination. Continued momentum in the PCV class has reinforced the size of the opportunity and demand for a PCV that increases disease coverage by protecting against both historically and currently circulating serotypes while maintaining robust immune responses. Taken together, this underscores our opportunity to improve public health as we prepare to enter an increasingly attractive commercial market. The unprecedented results from our Phase II study in adults demonstrated that VAX-31 may offer substantial improvement over existing products and achieve our objective to significantly expand disease coverage while maintaining high immunogenicity responses. And with the OPUS Phase III program underway, we believe that we are uniquely positioned to set a new standard by which future adult pneumococcal vaccines will be measured.
Frequently Asked Questions About PCVX
When is Vaxcyte's next earnings date?
Vaxcyte's next earnings report is expected for Feb 22, 2027.
Did PCVX beat earnings estimates last quarter?
No. Vaxcyte reported EPS of -$1.99 for the quarter ended Sep 30, 2026, below the -$1.84 estimate by 8.15%.
What EPS do analysts expect from PCVX next quarter?
The consensus EPS estimate for Vaxcyte for the quarter ending Dec 31, 2026 is -$2.01 from 12 analysts, with estimates from -$2.70 to -$0.90.
How often does PCVX beat earnings estimates?
Vaxcyte beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -16.92%.
PCVX pages: Overview, Earnings, Forecast, Financials, Competitors